ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08575
0,00%
Bitcoin
67.652,05
0,25%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) News

PBLA

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PBLA
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
15/05/202422h10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
01/05/202422h15GlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
30/04/202414h00GlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202422h39Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202422h36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202415h09Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202414h00GlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202422h31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202414h00GlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
17/04/202414h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
17/04/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
16/04/202423h29GlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
04/04/202422h17Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
03/04/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
29/03/202422h24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
29/03/202422h08Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202421h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
26/03/202421h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202421h10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202412h21IH Market NewsU.S. Index Futures on the Rise, Oil Prices Show StabilityNASDAQ:PBLAPanbela Therapeutics Inc
25/03/202421h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
12/03/202421h15GlobeNewswire Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024NASDAQ:PBLAPanbela Therapeutics Inc
07/03/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
15/02/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsNASDAQ:PBLAPanbela Therapeutics Inc
14/02/202402h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Kürzlich von Ihnen besucht

EU
1265T
1265T
LSE
52UZ
Cred Ag Co 26
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten